CervoMed Provides Update on Neflamapimod DLB Program as Part of Presentation at the 8th International Lewy Body Dementia Conference
Data from the first 16 weeks of the open-label extension phase of the RewinD-LB trial are expected in 1Q 2025 and will include data from ...
CervoMed to Present at the 8th International Lewy Body Dementia Conference
The details of the presentation will be accessible in the Investor section of the CervoMed website following the presentation. CervoMed Inc. is a clinical-stage company focused on developing ...